title: High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer.
abstract: High-dose chemotherapy with autologous stem cell transplantation has emerged as a common treatment for patients with breast cancer who have a poor prognosis. The success of this approach appears to depend on the tumor burden and the sensitivity of the disease to chemotherapy because treatment techniques have been refined and treatment-related mortality has declined. Phase II studies in patients with stage II and III disease are encouraging and suggest that treatment with high-dose chemotherapy before the development of metastatic disease may provide an advantage in terms of relapse-free and overall survival. However, tumor cells may contaminate stem cell collections and contribute to relapse after transplantation. Therefore it may be important to separate and select purified CD34+ cells which are not contaminated. It has been suggested that selection bias contributes to the favorable preliminary results observed in phase II studies of high-risk patients. Such issues, together with patient and physician bias regarding the benefits of this strategy, emphasize the need to complete the prospective randomized trials now underway.
authors.affiliation: Department of Medicine, Northwestern University Medical School, Robert H. Lurie Cancer Center, Chicago, IL 60611, USA. mtallman@casbah.acns.nwu.edu
authors.forename: M S
authors.initials: MS
authors.lastname: Tallman
authors.forename: W J
authors.initials: WJ
authors.lastname: Gradishar
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents